| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
2 companies
Merrill A McPeak is Director at RSSS, with reported holdings spanning 2 companies. Merrill A McPeak's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $3.7M at current prices.
Our model assigns Merrill A McPeak a middling insider score of 55/100, based on 6 past trades. Over a 12-month horizon, 50.0% of those trades were profitable, with an average 12-month return of +11.4%.
Merrill A McPeak's largest disclosed position is in IOVA as Director, worth about $2.8M. Net of sales, the IOVA filings show accumulation of 320,000 shares.
Merrill A McPeak has 46 Form 4 filings on record from February 2015 to November 2025, across 2 companies: Director at Research Solutions (RSSS), 2015–2025; Director at Iovance Biotherapeutics (IOVA), 2015–2024.
The 58 reported transactions were 24 option or other derivative awards, 23 open-market purchases, 8 option exercises and 2 open-market sales, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 15 purchases worth about $2.9M and 1 sale worth about $9K.
The largest open-market purchase was 250,000 shares of IOVA at an average $9.15 on February 20, 2024, about $2.3M. Twelve months later IOVA was down 53%.
The only open-market sale was 10,000 shares of RSSS at an average $0.89 on September 16, 2015, about $9K.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Feb 20, 2024 | IOVA Iovance Biotherapeutics, Inc. | Director | Buy | 250,000 | $9.15 | $2,287,500.00 | +356.4% | -14.0% | -53.0% | |
| Sep 18, 2023 | IOVA Iovance Biotherapeutics, Inc. | Director | Buy | 10,000 | $5.56 | $55,600.00 | +4.2% | +32.4% | +75.7% | |
| Dec 21, 2022 | IOVA Iovance Biotherapeutics, Inc. | Director | Buy | 10,000 | $6.15 | $61,500.00 | +16.6% | +4.0% | +30.4% | |
| Nov 29, 2022 | IOVA Iovance Biotherapeutics, Inc. | Director | Buy | 10,000 | $6.31 | $63,100.00 | +4.4% | +16.8% | -7.5% | |
| Nov 28, 2022 | IOVA Iovance Biotherapeutics, Inc. | Director | Buy | 10,000 | $6.18 | $61,800.00 | +4.6% | +20.5% | -6.4% | |
| May 31, 2022 | IOVA Iovance Biotherapeutics, Inc. | Director | Buy | 20,000 | $6.82 | $136,400.00 | +10.1% | +58.5% | +29.5% | |
| Dec 13, 2018 | IOVA Iovance Biotherapeutics, Inc. | Director | Buy | 10,000 | $9.63 | $96,273.00 | +2.2% | - | - | |
| Jun 24, 2016 | RSSS Research Solutions, Inc. | Director | Buy | 25,000 | $1.00 | $25,000.00 | +24.5% | - | - | |
| Mar 18, 2016 | RSSS Research Solutions, Inc. | Director | Buy | 10,000 | $0.75 | $7,500.00 | +10.9% | - | - | |
| Sep 16, 2015 | RSSS Research Solutions, Inc. | Director | Sell | 10,000 | $0.89 | $8,903.00 | -9.8% | - | - |